Pramipexole in Parkinson's disease. A short-term study using the combined levodopa-dopamine agonist test

Functional Neurology

Volumn 17, Issue 4, 2002, Pages 199-201

  Fabbrini, Giovanni ^a   Barbanti, Piero ^a   Aurilia, Cinzia ^a   Pauletti, Caterina ^a   Meco, Giuseppe ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Dopamine agonists; Levodopa; Parkinson's disease; Pramipexole

Indexed keywords

AMANTADINE; BENSERAZIDE; DOMPERIDONE; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; PRAMIPEXOLE; SELEGILINE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE DURATION; DISEASE SEVERITY; DOSE CALCULATION; DOSE TIME EFFECT RELATION; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; DYSKINESIA; HUMAN; LATENT PERIOD; MOTOR ACTIVITY; OPTIMAL DRUG DOSE; PARKINSON DISEASE; SHORT COURSE THERAPY; STIMULATION; TREMOR;

AGED; ANTIPARKINSON AGENTS; BENSERAZIDE; BENZOTHIAZOLES; DOPAMINE AGONISTS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; LEVODOPA; MALE; MOVEMENT; PARKINSON DISEASE; RECEPTORS, DOPAMINE D2; RECEPTORS, DOPAMINE D3; THIAZOLES;

EID: 0036821232     PISSN: 03935264     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Lesser RP, Fahn S, Snider SR, Cote LJ, Isgreen WP, Barrett RE. Analysis of the clinical problems in parkinsonism and the complications of long-term levodopa therapy. Neurology 1979;29:1253-1260
2. Lieberman A, Ranhosky A, Korts D. Clinical evaluation of pramipexole in advanced Parkinson's disease. Neurology 1997;49:162-168
3. Wermuth L and the Danish Pramipexole Study Group. A double-blind, placebo controlled, randomized, multi-center study of pramipexole in advanced Parkinson's disease. Eur J Neurol 1998;5:235-242
4. Olanow CW, Fahn S, Muenter M et al. A multicenter double-blind placebo controlled trial of pergolide as an adjunct to Sinemet in Parkinson's disease. Mov Disord 1994;1:40-47
5. Bonnet AM, Serre I, Marconi R, Agid Y, Dubois B. A "combined" levodopa test as a useful method for evaluating the efficacy of dopamine agonists: Application to pergolide and bromocriptine. Mov Disord 1995;5:668-671
6. Mierau J, Schingnitz G. Biochemical and pharmacological studies on pramipexole, a potent and selective dopamine D2 receptor agonist. Eur J Pharmacol 1992;215:161-170
7. Pinter MM, Pogarell O, Oertel WH. Efficacy, safety and tolerance of the non-ergoline dopamine agonist pramipexole in the treatment of advanced Parkinson's disease: A double blind, placebo controlled, randomised, multicentre study. J Neurol Neurosurg Psychiatry 1999;66:436-441
8. Guttman M. Double-blind comparison of pramipexole and bromocriptine treatment with placebo in advanced Parkinson's disease. The International Pramipexole-Bromocriptine Study Group. Neurology 1997;49:1060-1065
9. Grimes JD, King DB, Kofman OS, Molina-Negro P, Wilson AF, Bouchard S. Bromocriptine in the management of end of dose deterioration in Parkinson's disease. Can J Neurol Sci 1984;11:452-456
10. Lieberman A, Olanow CW, Sethi K et al. A multicenter trial of ropinirole as adjunct treatment for Parkinson's disease. Neurology 1998;51:1057-1062
11. Mouradian MM, Juncos JL, Fabbrini G, Schlegel J, Bartko JJ, Chase TN. Motor fluctuations in Parkinson's disease: Central pathophysiological mechanisms, part II. Ann Neurol 1988;24:372-378
12. Pinter MM, Rutgers AW, Hebenstreit E. An open label, multicentre clinical trial to determine the levodopa dose-sparing capacity of pramipexole in patients with idiopathic Parkinson's disease. J Neural Transm 2000;107:1307-1323
13. Pogarell O, Gasser T, Van Hilten JJ et al. Pramipexole in patients with Parkinson's disease and marked drug resistant tremor: A randomised, double blind, placebo controlled multicentre study. J Neurol Neurosurg Psychiatry 2002;72:713-720